Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06413953
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-05-08
Brief Title:
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Organization:
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Study Overview
Official Title:
A Phase I Clinical Study of Tolerability and Pharmacokinetics of TQB3107 Tablets in Patients With Malignant Tumors
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
TQB3107 is a protein inhibitor that induces apoptosis and inhibits the proliferation of various tumor cells This clinical study aims to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies to determine the dose-limiting toxicities DLTs maximum tolerated dose MTD if any and the recommended dose for Phase II RP2D
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None